Release Date: April 29, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: What kind of early pull-through are you seeing from your salesforce initiatives? A: Mike Quirk, Chief Scientific Officer, noted that they had a strong first quarter with over 20% growth in both demand and revenue. The salesforce expansion is complete, and they expect continued quarter-on-quarter revenue growth throughout the year. Chris Benecchi, Chief Operating Officer, added that the strategic decision to expand the sales organization aimed to broaden reach and increase contact frequency with healthcare professionals, particularly OBGYNs, who are crucial in peripartum care.
Q: Could you provide some additional color on the pipeline and your upcoming catalysts, particularly regarding SAGE's confidence in the GABA and NMDAR pathways? A: Laura Gault, Chief Medical Officer, explained that they recalibrated their R&D approach to focus on drugs with appropriate pharmacology for their intended indications. Mike Quirk added that they are prioritizing neuropsychiatry and neurodevelopmental disorders, leveraging clinical insights and validations. They believe their NMDA receptor NAMs can provide similar or better efficacy than existing treatments like ketamine, with improved safety and tolerability.
Q: For prescribers and patients not using ZURZUVAE as a first-line treatment, what are the key factors, and what efforts are underway to address these? A: Laura Gault stated that more than 70% of women prescribed ZURZUVAE receive it as their first new treatment for PPD. They do not see significant obstacles to ZURZUVAE becoming a frontline treatment. Chris Benecchi mentioned that the salesforce expansion has increased reach to OBGYNs, leading to more new writers who become repeat prescribers.
Q: How should we look at inventory levels for ZURZUVAE, and when can we expect them to stabilize? A: Chris Benecchi explained that inventory levels fluctuate due to wholesalers' purchasing habits. The focus should be on demand, measured by shipments from specialty pharmacies to women with PPD. They are encouraged by the more than 3,000 shipments in the first quarter, reflecting strong uptake and interest in ZURZUVAE.
Q: What is the overall awareness of ZURZUVAE among OBGYNs and the expecting mother community, and how is screening for PPD increasing? A: Chris Benecchi reported approximately 90% aided awareness of ZURZUVAE among physicians treating PPD, which is high for this stage of launch. They are working to increase awareness through personal and non-personal promotion. There has been an uptick in screening and diagnosis among prescribers of ZURZUVAE, indicating a renewed interest in addressing PPD.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.